arsenic trioxide medac
medac gesellschaft für klinische spezialpräparate mbh - il triossido di arsenico - leucemia, promielocitica, acuta - agenti antineoplastici - arsenic trioxide medac is indicated for induction of remission, and consolidation in adult patients with:newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (apl) (white blood cell count, ≤ 10 x 10³/μl) in combination with all-trans-retinoic acid (atra)relapsed/refractory apl (previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the pro-myelocytic leukaemia/retinoic-acid-receptor-alpha (pml/rarα) gene. il tasso di risposta di altri mieloide acuta leucemia sottotipi di triossido di arsenico non è stato esaminato.
biomineral plus integratore alimentare 60 capsule
meda pharma spa -
breakyl
meda pharma s.p.a. - fentanil - fentanil
adamon
meda pharma s.p.a. - tramadolo - tramadolo
lasticom
meda pharma gmbh & co. kg - azelastina - azelastina
librax
meda pharma s.p.a. - clidinio e psicolettici - clidinio e psicolettici
proxil
meda pharma s.p.a. - proglumetacina - proglumetacina
bacacil
meda pharma s.p.a. - bacampicillina - bacampicillina
normison
meda pharma s.p.a. - derivati benzodiazepinici - derivati benzodiazepinici
tilcotil
meda pharma s.p.a. - tenoxicam - tenoxicam